NeuroScientific Biopharmaceuticals (NSB) Investor Presentation summary

Financial position and leadership

• Market capitalization is approximately $50 million with $7.3 million in cash as of October 2025.

• Leadership team has extensive experience in biologics, cell therapies, finance, and governance.

StemSmart™ technology and clinical progress

• StemSmart™ is a patented MSC platform with global IP, manufactured in TGA-accredited facilities.

• Demonstrated 78% overall response rate in refractory Crohn's trial with strong safety profile.

• Special Access Program for Crohn's Fistulas commenced June 2025, informing future Phase 2 trials.

Market opportunity and pipeline

• Addressable markets include Crohn's disease ($13.8B by 2026), kidney transplant, lung disorders, and GvHD.

• Expansion to high-value indications is planned, with a total market opportunity of $35–40 billion.